Business Wire

Business Figures for the First Half of 2018: Sartorius Records Double-Digit Sales Growth

Del

Sartorius, a leading international partner of the biopharmaceutical industry and the research sector, continued on the growth track, with significant increases in sales revenue and earnings. “The first half of 2018 was very successful overall for Sartorius,” commented CEO Joachim Kreuzburg on the results after six months. “We grew dynamically in our two divisions and in all regions and, despite currency headwinds, further increased our profit margin. Due to the dynamics that were slightly above our expectations in Bioprocess Solutions, we have raised our sales forecast for this division and thus for the entire Group.”

Business development of the Sartorius Group

In the first half of 2018, Sartorius increased its sales revenue by 11.9% (reported: +8.0%) in constant currencies to 758.4 million euros. Acquisitions contributed around 2 percentage points to this positive business performance. Order intake rose somewhat more strongly than sales revenue and was up 12.7% (reported: +8.9%).

Regionally, the Americas recorded the highest dynamics. Sales in this region were up 16.6% to 249.6 million euros, relative to a moderate revenue base in the previous year. In Asia|Pacific, Sartorius also grew by double digits, with sales up 12.2% to 184.4 million euros, while the company achieved higher revenue in the EMEA2) region, recording 324.4 million euros, 8.4% up from the comparable period a year ago (regional growth rates in constant currencies).

Earnings also increased robustly: Underlying EBITDA rose 9.6% to 189.5 million euros, despite negative currency effects that occurred especially in the first quarter. The Group’s underlying EBITDA margin improved to 25.0% compared with 24.6% a year ago. Relevant net profit3) for the Group grew even more significantly, by 14.1% from 69.9 million euros to 79.8 million euros. This corresponds to earnings per ordinary share of 1.16 euros (H1 2017: 1.02 euros) and per preference share of 1.17 euros (H1 2017: 1.03 euros).

The Group's key financial indicators continued to remain at robust levels. At the end of the reporting period, the company's equity ratio was 34.9% and its ratio of net debt to underlying EBITDA1) stood at 2.6 (Dec. 31, 2017: 35.1% and 2.5, respectively). The first-half capex ratio was 13.2%, approximately at the previous year’s level and thus within the planned range. Investment activities continued to focus on expansion of the plant for manufacturing single-use bags and filters in Puerto Rico, as well as on the combination and expansion of Group headquarters and production capacity levels in Göttingen, Germany.

As of the reporting date on June 30, 2018, Sartorius employed 7,738 people worldwide, 237 more than as of December 31, 2017 (approx. +3%).

Business development of the divisions

The Bioprocess Solutions Division, which offers a wide array of innovative technologies for the manufacturing of biopharmaceuticals, recorded sales growth of 11.9% in constant currencies to 550.3 million euros (reported: +7.9%) after dynamic business performance in the second half. Consolidation of Umetrics acquired in the previous year contributed close to one percentage point of non-organic growth to sales expansion. Order intake also rose slightly more strongly than expected, up 12.6% in constant currencies (reported: +8.7%).

Underlying EBITDA for the division increased by 10.0% to 153.9 million euros due to economies of scale and despite negative currency effects. The division's corresponding margin was 28.0% relative to 27.4% in the prior-year period.

The Lab Products & Services Division, which offers products and technologies for laboratories primarily in the pharma sector and for life science research, grew by double digits, with sales up 12.0% in constant currencies (reported: +8.1%) to 208.1 million euros. While the division’s organic growth was around 7%, the prior-year acquisition of Essen BioScience, a specialist in cell analysis, contributed non-organic growth of around 5 percentage points. First-half order intake for the division was up 13.1% in constant currencies (reported: +9.2%).

Recording a gain of 7.8%, Lab Products & Services increased its underlying EBITDA from 33.0 million euros to 35.5 million euros. Within the context of the less favorable currency environment its margin remained at the prior-year figure of 17.1%.

Forecast for the full year of 2018 raised

In view of strong business performance in the first half of 2018, management has raised its sales forecast for the Bioprocess Solutions Division and thus for the entire Group. Consolidated sales revenue is projected to grow by about 12% to 15% (previous guidance: 9% to 12%). The Group’s underlying EBITDA margin is still expected to increase by 0.5 percentage points compared with the year-earlier figure of 25.1%.

Given the dynamic growth of sales revenue and order intake in the first half for the Bioprocess Solutions Division, management now projects that division sales will increase by about 12% to 15% (previous guidance about 8% to 11%). This figure includes a non-organic growth contribution of slightly less than 0.5 percentage points. The division's underlying EBITDA margin is forecasted to gain about half a percentage point over the prior-year figure of 28.0%.

For the Lab Products & Services Division, guidance remains unchanged. Sartorius expects division sales to grow by about 12% to 15%, which includes more than 2.5 percentage points of non-organic growth expected to be contributed by Essen BioScience that was consolidated as of the end of March in 2017. The division’s underlying EBITDA margin is projected to rise by around one percentage point (previous year: 18.0%).

All forecasts are based on constant currencies. Due to the latest foreign exchange developments, our results reported in actual currencies may differ. We will explain any particular effects that occur during 2018.

1) Sartorius uses underlying EBITDA (earnings before interest, taxes, depreciation and amortization; adjusted for extraordinary items) as the key profitability indicator
2) EMEA = Europe | Middle East | Africa
3) After non-controlling interest, adjusted for extraordinary items and non-cash amortization, as well as based on the normalized financial result and corresponding tax effects.

This press release contains statements about the future development of the Sartorius Group. The content of these statements cannot be guaranteed as they are based on assumptions and estimates that harbor certain risks and uncertainties. This is a translation of the original German-language press release. Sartorius shall not assume any liability for the correctness of this translation. The original German press release is the legally binding version. Furthermore, Sartorius reserves the right not to be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.

Current image files

Joachim Kreuzburg, CEO and Executive Board Chairman of Sartorius AG
www.sartorius.com/fileadmin/media/global/company/Sartorius_Kreuzburg.jpg

Sartorius products used in the manufacture of medications
https://www.sartorius.com/mediafile/corp/Sartorius_0232_PG9_01_RGB.jpg

Sartorius products used in pharmaceutical research
www.sartorius.com/mediafile/corp/Sartorius_0424_PG14.jpg

Conference call

Joachim Kreuzburg, CEO and Executive Board Chairman of Sartorius, and Rainer Lehmann, CFO of Sartorius, will discuss the company's business results with analysts and investors on Tuesday, July 24, 2018, at 3:30 p.m. Central European Time (CET) in a teleconference. You may register by clicking on the following link:
http://services.choruscall.de/DiamondPassRegistration/register?confirmationNumber=2924053&linkSecurityString=122e29ee9

Alternatively, you can dial into the teleconference, without registering, at:
+49 (0) 69 566 03 6000

The company presentation will be available on July 24, 2018, starting at 3:15 p.m. CET, for viewing on our website at:
http://www.sartorius.com/com/group/investor-relations/sartorius-ag/

Upcoming financial date:

October 23, 2018 Publication of nine-month figures (January to September 2018)

A profile of Sartorius

The Sartorius Group is a leading international pharmaceutical and laboratory equipment provider with two divisions: Bioprocess Solutions and Lab Products & Services. Bioprocess Solutions with its broad product portfolio focusing on single-use solutions helps customers produce biotech medications and vaccines safely and efficiently. Lab Products & Services, with its premium laboratory instruments, consumables and services, concentrates on serving the needs of laboratories performing research and quality assurance at pharma and biopharma companies and on those of academic research institutes. Founded in 1870, the company earned sales revenue of more than 1.4 billion euros in 2017. More than 7,500 people work at the Group's approximately 50 manufacturing and sales sites, serving customers around the globe.

Key Figures for the First Half of 2018

             
Sartorius Group Bioprocess Solutions Lab Products & Services
In millions of € (unless otherwise specified)      

H1
2018

    H1
20175)
   

Δ∆ in %
Reported

   

Δ∆ in %
cc1)

    H1
2018
    H1
20175)
   

Δ∆ in %
Reported

     

Δ∆ in %
cc1)

    H1
2018
    H1
20175)
   

Δ∆ in %
Reported

   

Δ∆ in %
cc1)

Sales Revenue and Order Intake
Sales revenue       758.4     702.5     8.0     11,9     550.3     510.1     7.9       11,9     208.1     192.4     8.1     12.0

- EMEA2)

      324.4     301.8     7.5     8,4     229.5     208.5     10.0       10,7     94.9     93.3     1.8     3.3
- Americas2)       249.6     228.5     9.3     16,6     195.8     181.3     8.0       15,4     53.9     47.2     14.1     20.9
- Asia | Pacific2)       184.4     172.2     7.1     12,2     125.1     120.3     4.0       8,9     59.3     51.9     14.2     19.9
Order intake       807.6     741.9     8.9     12,7     594.6     546.9     8.7       12,6     213.0     195.0     9.2     13.1
Earnings
EBITDA3)       189.5     172.9     9.6           153.9     140.0     10.0             35.5     33.0     7.8      
EBITDA margin3) in %       25.0     24.6                 28.0     27.4                   17.1     17.1            
Net profit for the period4)       79.8     69.9     14.1                                                        
Financial Data per Share

Earnings per ordinary share4) in €

      1.16     1.02     14.1                                                        

Earnings per preference share4) in €

      1.17     1.03     14.0                                                        
 

1) In constant currencies

2) Acc. to the customer’s location

3) Adjusted for extraordinary items

4) After non-controlling interest, adjusted for extraordinary items and non-cash amortization, as well as based on the normalized financial result and corresponding tax effects

5) The previous year's figures have been restated due to the finalization of the purchase price allocations for the acquisitions of 2017

 

Contact information

Sartorius AG
Petra Kirchhoff, +49 (0)551.308.1686
Head of Corporate Communications
petra.kirchhoff@sartorius.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Hilton Launches New Brand, Signia Hilton, Delivering Sophisticated Travel While Reimagining Meetings and Events22.2.2019 17:00:00Pressemelding

Hilton (NYSE: HLT) today announced the launch of Signia Hilton, its dynamic, new meetings-and-events-focused brand. The portfolio of hotels is setting out to transform the industry for meeting professionals and sophisticated business travelers by infusing state-of-the-art technology and design into every aspect of the guest experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190222005071/en/ The brand further reinforces Hilton’s commitment to innovation that meets the evolving needs of today’s travelers and will bring premium experiences to top urban and resort destinations around the world. “In our 100th year of hospitality, we are more focused than ever on providing exceptional experiences to all of our guests – and that includes evolving those experiences to meet their changing needs,” said Christopher J. Nassetta, president and CEO, Hilton. “We are proud to launch Signia Hilton, which exemplifies our innovative sp

Axonics® Granted Expanded CE Mark Label; First and Only Sacral Neuromodulation System Approved for Use with Full-Body MRI Scans22.2.2019 16:30:00Pressemelding

Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, announced today that it has received CE mark approval for 1.5T and 3T full-body magnetic resonance imaging (“MRI”) conditional labeling for the Axonics r-SNM® System. The Axonics r-SNM System is the only implantable SNM system that has received full-body MRI conditional labeling for sale in Europe1. Raymond W. Cohen, Chief Executive Officer of Axonics, said, “Without this labeling, any patient requiring an MRI scan on any body part below the head must have their neurostimulator surgically explanted prior to the MRI scan, resulting in an additional surgery for the patient and additional costs to patients and the healthcare system. This authorization of full-body MRI scans in Europe is another important milestone for Axonics, differentiating our te

Fantastec Joins Forces with Arsenal FC Launching Official Blockchain Collectibles App22.2.2019 14:30:00Pressemelding

Fantastec announced today its first football licensing agreement with Premier League club Arsenal FC for a new blockchain authenticated collectibles app called Fantastec SWAP. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190222005277/en/ Arsenal players appear on Fantastec SWAP in official licensing deal (Graphic: Business Wire) London-based Fantastec is a leading sports fan technology innovator, and its blockchain based ‘SWAP’ app will have broad appeal to global sports fans, gamers and sports card collectors alike. Fantastec SWAP unlocks unique and authentic club content through the app, like player autographs and exclusive footage. With its innovative blockchain technology, fans around the world can now discover, collect and swap officially licensed club collectibles with other fans with complete trust. “Fantastec SWAP is a game-changer for international football fans as well the sports collectibles industry,” commented

Volkswagen Protects Virtual Key Sharing App with Trustonic Application Protection22.2.2019 13:42:00Pressemelding

Volkswagen is working with mobile cyber security leader Trustonic to enable customers to use smartphones to access their vehicles, and to securely share their digital car keys to grant access to others via a smartphone app. Volkswagen is using the Trustonic Application Protection (TAP) platform to secure the mobile app and ensure that sensitive information and key transfer requests are securely displayed to, and approved by, a real authenticated user on a trusted device and not by hackers or malware simulating a user or device. “The smartphone is becoming the vehicle key of the future and our We Connect service is the interface for this today in the new Volkswagen Passat,” comments Alf Pollex, Head of Infotainment and Connected Car at Volkswagen AG. “The user installs the We Connect app on their smartphone which is then authorized via the infotainment system with a Transaction Number. The Mobile Key will be compatible with Android-based Samsung devices. No mobile network connection is

Mundipharma EDO GmbH: US FDA grants Orphan Drug Designation for etoposide toniribate in relapsed/refractory biliary tract cancer22.2.2019 13:30:00Pressemelding

Mundipharma EDO GmbH, part of the Mundipharma network of independent associated companies, and Imbrium Therapeutics L.P., an operating subsidiary of Purdue Pharma L.P., today announced that the US FDA has granted Orphan Drug Designation (ODD) to etoposide toniribate for the treatment of relapsed/refractory biliary tract cancer, also known as cholangiocarcinoma.3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190222005126/en/ Biliary tract cancer is a rare tumour with approximately 8,000 patients diagnosed in the US every year and 10,571 in Europe.4,5 The FDA grants ODD status to medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US. Radical surgery is the only curative treatment for biliary tract cancer but, in most cases, the cancer is inoperable. Patients who fail first-line chemotherapy have limited treatment options and the standard of

Lenovo Data Center Group Delivers Broad Edge Computing Portfolio, Expands Investments in IoT22.2.2019 13:13:00Pressemelding

Next week at MWC Barcelona, Lenovo Data Center Group (DCG) will showcase continued investments in its solutions supporting IoT and edge computing as part of its IoT growth plan over the next few years. Building on the momentum of its fifth consecutive quarter of profit growth, Lenovo DCG is building a portfolio that takes infrastructure to where the data is, whether that be in the traditional data center, in the cloud or increasingly, at the edge. Today, around 10 percent of enterprise-generated data is created and processed outside a traditional centralized data center or cloud. By 2022, Gartner predicts this figure will reach 75 percent. This migration is driving increased concerns around data privacy, security and regulations coupled with challenges of latency, bandwidth and downtime. Lenovo is addressing these challenges by creating a broad portfolio of edge computing offerings that address the different ways that customers want to deploy edge computing solutions for IoT use cases.